{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:35:26Z","timestamp":1785418526523,"version":"3.56.0"},"reference-count":50,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002865","name":"Chongqing Science and Technology Commission","doi-asserted-by":"crossref","award":["CSTB2021TIAD-KPX0041"],"award-info":[{"award-number":["CSTB2021TIAD-KPX0041"]}],"id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"crossref"}]},{"award":["CSTB2021TIAD-KPX0041"],"award-info":[{"award-number":["CSTB2021TIAD-KPX0041"]}],"id":[{"id":"https:\/\/ror.org\/05w9erc61","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Aberrant glycosylation is closely associated with tumor progression, changes in the tumor microenvironment, and chemoresistance. This study aimed to identify prognostic sialylation-related genes in bladder cancer and define the role of ST3GAL6 in gemcitabine\u2013cisplatin resistance. Methods: Molecular subtype analysis, prognostic analysis, and risk model construction were performed for sialylation-related genes using transcriptomic data and clinical information from the TCGA database. GC-resistant bladder cancer cell models were established for transcriptomic sequencing and untargeted metabolomic analysis. Cell proliferation and drug sensitivity assays were performed to evaluate the function of ST3GAL6. The regulatory relationship between IGF2BP3, ST3GAL6, and the PI3K pathway was further assessed by combining database analysis with molecular experiments. Results: Sialylation-related molecular patterns were associated with patient prognosis and tumor microenvironment features, particularly fibroblast-related characteristics, in bladder cancer. The key model gene ST3GAL6 was upregulated in bladder cancer tissues and was closely associated with prognosis. In GC-resistant bladder cancer cells, ST3GAL6 expression was significantly increased and accompanied by enhanced sialylation activity. ST3GAL6 promoted bladder cancer cell proliferation and reduced sensitivity to cisplatin and gemcitabine, at least in part through the PI3K-AKT-mTOR pathway. IGF2BP3 was also upregulated in resistant cells, is positively correlated with ST3GAL6, and may help maintain ST3GAL6\u2019s expression by stabilizing its mRNA. Conclusions: Our findings suggest that aberrant sialylation is involved in bladder cancer progression and GC resistance. The IGF2BP3-ST3GAL6-PI3K\/AKT\/mTOR signaling axis may contribute to this process and may serve as a potential biomarker and therapeutic target in bladder cancer.<\/jats:p>","DOI":"10.3390\/cancers18111713","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:30:33Z","timestamp":1779669033000},"page":"1713","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Abnormal Sialylation Promotes Chemotherapy Resistance in Bladder Cancer via the PI3K-AKT-mTOR Signaling Pathway"],"prefix":"10.3390","volume":"18","author":[{"given":"Junlong","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinghao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijia","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyang","family":"He","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.eururo.2025.12.011","article-title":"Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends","volume":"89","author":"Filho","year":"2026","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Hansel","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2023.41.6_suppl.439","article-title":"Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer","volume":"41","author":"Milowsky","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline: 2024 Amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","article-title":"Global trends in the epidemiology of bladder cancer: Challenges for public health and clinical practice","volume":"20","author":"Vrieling","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Munkley, J. (2022). Aberrant Sialylation in Cancer: Therapeutic Opportunities. Cancers, 14.","DOI":"10.3390\/cancers14174248"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41420-024-02180-3","article-title":"Biological function of sialic acid and sialylation in human health and disease","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell Death Discov."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Habeeb, I.F., Alao, T.E., Delgado, D., and Buffone, A. (2024). When a negative (charge) is not a positive: Sialylation and its role in cancer mechanics and progression. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1487306"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101112","DOI":"10.1016\/j.mam.2022.101112","article-title":"Siglec receptors as new immune checkpoints in cancer","volume":"90","author":"Stanczak","year":"2023","journal-title":"Mol. Asp. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.trecan.2023.11.009","article-title":"Targeting myeloid cells for cancer immunotherapy: Siglec-7\/9\/10\/15 and their ligands","volume":"10","author":"Boelaars","year":"2024","journal-title":"Trends Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Feng, H., Feng, J., Han, X., Ying, Y., Lou, W., Liu, L., and Zhang, L. (2024). The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy. Cancers, 16.","DOI":"10.3390\/cancers16020289"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.apsb.2023.10.014","article-title":"The role of N-glycosylation in cancer","volume":"14","author":"Lin","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wilczak, M., Surman, M., and Przyby\u0142o, M. (2023). Altered Glycosylation in Progression and Management of Bladder Cancer. Molecules, 28.","DOI":"10.3390\/molecules28083436"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"112569","DOI":"10.1016\/j.intimp.2024.112569","article-title":"Identification and validation of sialyltransferase ST3Gal5 in bladder cancer through bioinformatics and experimental analysis","volume":"138","author":"Jian","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s40001-023-01496-7","article-title":"A sialyltransferases-related gene signature serves as a potential predictor of prognosis and therapeutic response for bladder cancer","volume":"28","author":"Cao","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/s41467-025-57633-9","article-title":"Urinary extracellular vesicle N-glycomics identifies diagnostic glycosignatures for bladder cancer","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1002\/mco2.715","article-title":"Role of N6-methyladenosine RNA modification in cancer","volume":"5","author":"Qu","year":"2024","journal-title":"MedComm"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12943-023-01782-2","article-title":"The role of m6A methylation in therapy resistance in cancer","volume":"22","author":"Zhuang","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"115477","DOI":"10.1016\/j.biopha.2023.115477","article-title":"N6-methyladenosine (m6A) in cancer therapeutic resistance: Potential mechanisms and clinical implications","volume":"167","author":"Wang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1186\/s12967-024-05701-x","article-title":"Dynamic landscape of m6A modifications and related post-transcriptional events in muscle-invasive bladder cancer","volume":"22","author":"Zhang","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10495-023-01817-5","article-title":"m6A writer WTAP targets NRF2 to accelerate bladder cancer malignancy via m6A-dependent ferroptosis regulation","volume":"28","author":"Wang","year":"2023","journal-title":"Apoptosis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.7150\/ijbs.86719","article-title":"METTL16 suppressed the proliferation and cisplatin-chemoresistance of bladder cancer by degrading PMEPA1 mRNA in a m6A manner through autophagy pathway","volume":"20","author":"Yu","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12967-023-04805-0","article-title":"PIGT promotes cell growth, glycolysis, and metastasis in bladder cancer by modulating GLUT1 glycosylation and membrane trafficking","volume":"22","author":"Tan","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hugonnet, M., Singh, P., Haas, Q., and von Gunten, S. (2021). The Distinct Roles of Sialyltransferases in Cancer Biology and Onco-Immunology. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.799861"},{"key":"ref_26","first-page":"100777","article-title":"The fate of orally administered sialic acid: First insights from patients with N-acetylneuraminic acid synthase deficiency and control subjects","volume":"28","author":"Tran","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Szulc, B., Zadorozhna, Y., Olczak, M., Wiertelak, W., and Maszczak-Seneczko, D. (2020). Novel Insights into Selected Disease-Causing Mutations within the SLC35A1 Gene Encoding the CMP-Sialic Acid Transporter. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010304"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1021\/acs.jmedchem.1c01612","article-title":"Human Neuraminidases: Structures and Stereoselective Inhibitors","volume":"65","author":"Bourguet","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"109242","DOI":"10.1016\/j.carres.2024.109242","article-title":"Putting a cap on the glycome: Dissecting human sialyltransferase functions","volume":"544","author":"Mohamed","year":"2024","journal-title":"Carbohydr. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): Survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines","volume":"85","author":"Cathomas","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41585-024-00914-7","article-title":"Molecular biomarkers of progression in non-muscle-invasive bladder cancer-beyond conventional risk stratification","volume":"22","author":"Olislagers","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s00432-024-05623-7","article-title":"Current look at the most promising proteomic and glycomic biomarkers of bladder cancer","volume":"150","author":"Harsanyi","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e180282","DOI":"10.1172\/JCI180282","article-title":"Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer","volume":"134","author":"Wen","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10078","DOI":"10.7150\/thno.48711","article-title":"Identification of glycogene-type and validation of ST3GAL6 as a biomarker predicts clinical outcome and cancer cell invasion in urinary bladder cancer","volume":"10","author":"Dalangood","year":"2020","journal-title":"Theranostics"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ijc.32103","article-title":"LncRNA ST3Gal6-AS1\/ST3Gal6 axis mediates colorectal cancer progression by regulating \u03b1-2,3 sialylation via PI3K\/Akt signaling","volume":"145","author":"Hu","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cas.13128","article-title":"Sialyltransferase ST3GAL6 mediates the effect of microRNA-26a on cell growth, migration, and invasion in hepatocellular carcinoma through the protein kinase B\/mammalian target of rapamycin pathway","volume":"108","author":"Sun","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12943-022-01500-4","article-title":"The role of m6A RNA methylation in cancer metabolism","volume":"21","author":"An","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1186\/s12967-023-04651-0","article-title":"Role of m6A modification in regulating the PI3K\/AKT signaling pathway in cancer","volume":"21","author":"Liu","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Liu, X., Chen, J., Chen, W., Xu, Y., Shen, Y., and Xu, X. (2023). Targeting IGF2BP3 in Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119423"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.7150\/ijbs.103522","article-title":"IGF2BP3 promotes the proliferation and cisplatin resistance of bladder cancer by enhancing the mRNA stability of CDK6 in an m6A dependent manner","volume":"21","author":"Song","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s13577-024-01136-0","article-title":"N6-methyladenosine-modified SRD5A3, identified by IGF2BP3, sustains cisplatin resistance in bladder cancer","volume":"38","author":"Liao","year":"2024","journal-title":"Hum. Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s11658-024-00545-1","article-title":"IGF2BP3 prevent HMGB1 mRNA decay in bladder cancer and development","volume":"29","author":"Lv","year":"2024","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"100075","DOI":"10.1016\/j.cellin.2022.100075","article-title":"Intertwined regulation between RNA m6A modification and cancer metabolism","volume":"2","author":"Liu","year":"2023","journal-title":"Cell Insight"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer","volume":"85","author":"Yu","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Peng, Y., Wang, Y., Zhou, C., Mei, W., and Zeng, C. (2022). PI3K\/Akt\/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.819128"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Zhu, J., Tong, H., Sun, Y., Li, T., Yang, G., and He, W. (2023). YTHDF1 Promotes Bladder Cancer Cell Proliferation via the METTL3\/YTHDF1-RPN2-PI3K\/AKT\/mTOR Axis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24086905"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/tox.24153","article-title":"PRDX2 regulates stemness contributing to cisplatin resistance and metastasis in bladder cancer","volume":"39","author":"Li","year":"2024","journal-title":"Environ. Toxicol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s12935-020-01660-7","article-title":"Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K\/Akt\/mTOR pathway: Go four better to treat bladder cancer","volume":"20","author":"Khan","year":"2020","journal-title":"Cancer Cell Int."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1713\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:20:12Z","timestamp":1779769212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18111713"],"URL":"https:\/\/doi.org\/10.3390\/cancers18111713","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,24]]}}}